Yale University School of Medicine: Section of Rheumatology
Welcome,         Profile    Billing    Logout  
 3 Trials 
21 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McMahon, Maureen
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Terminated
3
275
Europe, Canada, Japan, US, RoW
secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Lupus Nephritis
09/23
09/23
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated
2
9
US
Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin
National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
04/24
04/24
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Recruiting
1/2
30
US, RoW
IMPT-514
ImmPACT Bio
Systemic Lupus Erythematosus, Lupus Nephritis
02/27
02/27
Koumpouras, Fotios
SIRIUS-SLE 1, NCT05639114 / 2022-002691-36: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
406
Europe, Canada, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
04/29
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
NCT04486118: Centrally Acting ACE Inhibition in SLE

Active, not recruiting
2
36
US
Lisinopril Pills, Benazepril Pill
Northwell Health, Lupus Research Alliance
Systemic Lupus Erythematosus
06/25
11/25
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated
2
9
US
Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin
National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
04/24
04/24
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
NCT00775476: Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Recruiting
2
290
US
N-acetylcysteine, Placebo
State University of New York - Upstate Medical University, Cedars-Sinai Medical Center, University of Rochester, Yale University, Penn State University, Hospital for Special Surgery, New York, Ohio State University, Oklahoma City VA Health Care System, St. Luke's Hospital and Health Network, Pennsylvania
Systemic Lupus Erythematosus
03/27
09/28
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27
NAIVE, NCT04726553: Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

Recruiting
1
20
US
Anifrolumab, Medi 546, Standard of Care, azathioprine, methotrexate, mycophenolate mofetil, corticosteroids, antimalarials
Oklahoma Medical Research Foundation, NYU Langone Health, Yale University, Piedmont Heart Institute, Inc., Atlanta, GA, Columbia University
Systemic Lupus Erythematosus (SLE)
12/23
12/24
ReLATE, NCT05845593: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE

Recruiting
N/A
200
US
Decision Support Test
Ampel BioSolutions, LLC
Lupus Erythematosus, Systemic
12/24
03/25
Heffernan, Julie
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
NCT04486118: Centrally Acting ACE Inhibition in SLE

Active, not recruiting
2
36
US
Lisinopril Pills, Benazepril Pill
Northwell Health, Lupus Research Alliance
Systemic Lupus Erythematosus
06/25
11/25
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated
2
9
US
Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin
National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
04/24
04/24
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
NCT00775476: Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

Recruiting
2
290
US
N-acetylcysteine, Placebo
State University of New York - Upstate Medical University, Cedars-Sinai Medical Center, University of Rochester, Yale University, Penn State University, Hospital for Special Surgery, New York, Ohio State University, Oklahoma City VA Health Care System, St. Luke's Hospital and Health Network, Pennsylvania
Systemic Lupus Erythematosus
03/27
09/28
ReLATE, NCT05845593: Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE

Recruiting
N/A
200
US
Decision Support Test
Ampel BioSolutions, LLC
Lupus Erythematosus, Systemic
12/24
03/25

Download Options